Immunoglobulins in PID, SID and neurological autoimmune disease;Anwendung von Immunglobulinen bei primären und sekundären Immundefekten und neurologischen Autoimmunerkrankungen

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 13, 2012, Pages 675-680

  Borte, M ^a   Baumann, U ^b   Pittrow, D ^c   Hensel, M ^d   Fasshauer M ^a   Huscher, D ^e   Reiser, M ^f   Stangel, M ^b   Gold, R ^g   Kirch, W ^c  

^a Klinikum St Georg   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Mannheimer Onkologie Praxis   (Germany)

^e Rheumaforschungszentrum Berlin ^*  (Germany)

^f PIOH Praxis Internistische Onkologie   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

Author keywords

immunodeficiency; management; neuroimmunology; Observational; outcomes research; patient related outcomes; pharmacoeconomics; quality of life

Indexed keywords

IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; NEUROLOGIC DISEASE; REVIEW;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; COHORT STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS;

EID: 84858412155     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1304844     Document Type: Review

References (40)

1. Anthony RM, Kobayashi T, Wermeling F et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature: 2011; 475 110 113
2. Borte M, Bernatowska E, Ochs HD et al. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol: 2011; 164 357 364
3. Borte M, Quinti I, Soresina A et al. Efficacy and safety of subcutaneous vivaglobin(R) replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol: 2011; 31 952 961
4. Bruton O. Agammaglobulinemia. Pediatrics: 1952; 9 722 727
5. Bullinger M, Schmidt S, Petersen C et al. Methodische Herausforderungen und Potentiale der Evaluation gesundheitsbezogener Lebensqualitat fur Kinder mit chronischen Erkrankungen im medizinischen Versorgungssystem. Med Klin: 2007; 102 734 745 (Pubitemid 47459830)
6. Cats EA, van der Pol WL, Piepers S et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology: 2010; 75 818 825
7. Cats EA, van der Pol WL, Piepers S et al. New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuroathy: a prospective study of efficacy, safety and tolerability. J Neurol: 2008; 255 1598 1599
8. Chapel H, Lee M, Hargreaves R et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet: 1994; 343 1059 1063 (Pubitemid 24128204)
9. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med: 1988; 319 902 907
10. Deutsche Selbsthilfe Angeborene Immundefekte Internet: www.dsai.de Zugriff am 2.2.2012.
11. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol: 1994; 97 01 79 83 (Pubitemid 24235272)
12. Einsele H, Naumann R, Goldschmidt H et al. DGHO-Leitlinie Multiples Myelom. Stand Dezember 2009. http://www.dgho-onkopedia.de. Zugriff am 8.3.2012.
13. Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol: 2008; 15 893 908
14. European Medicines Agency (EMA) European Medicines Agency recommends suspension of Octagam in all EU Member States. (press release 24.9.2010). http://www.ema.europa.eu. Zugriff am 8.3.2012.
15. Geha RS, Notarangelo LD, Casanova JL et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol: 2007; 120 776 794
16. Gras V, Andrejak M, Decocq G. Acute renal failure associated with intravenous immunoglobulins. Pharmacoepidemiol Drug Saf: 1999; 8 01 73 78
17. Gröner A, Caspari G. Pathogeneliminierung und -inaktivierung bei der Herstellung von Plasmaderivaten (Kapitel 15). In: Kramer A, Assadian O. Hrsg. Wallhäußers Praxis der Sterilisation, Desinfektion, Antiseptik und Konservierung. Thieme Verlag: 2008
18. Hallek M, Eichhorst B, Dreger P. DGHO-Leitlinie Chronische Lymphatische Leukämie. Stand 13.12.2006. http://www.dgho-onkopedia.de Zugriff am 8.3.2012.
19. Hammarström L. Prävalenz, Screening und Diagnose von PIDs in der EU. In: European Primary Immunodeficiencies Consensus Conference: Consensus Report and Recommendations. http://ec.europa.eu Zugriff am 8.3.2012.
20. Harbo T, Andersen H, Hess A et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol: 2009; 16 631 638
21. Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol: 2009; 7 337 342
22. Kirch W, Stangel M, Pittrow D et al. Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry. J Public Health: 2012; (im Druck)
23. Knerr V, Gathmann B, Eades-Perner AM et al. Die ESID-Online-Datenbank fur primare Immundefekte: Erste Analysen mit Blick auf Deutschland und Europa. Med Klin: 2008; 103 620 627
24. Lin RY, Rodriguez-Baez G, Bhargave GA et al. Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004-2009. Clin Nephrol: 2011; 76 365 372
25. Mapi Research Trust Patient-reported Outcome and Quality of Life Instruments Database. Internet: http://www.proqolid.org Zugriff am 2.3.2012.
26. Ochs H D, Siegel J, Young H. Stabilizers used in intravenous immunoglobulin products: a comparative review. Pharmacy Practice News. August 2010 McMahon Publishing USA http://www.pharmacypracticenews.com Zugriff am 1. März 2012.
27. Onuigbo MA. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case-control study. Pharmacoepidemiol Drug Saf: 2012; doi: 10.1002/pds.2273
28. Orange JS, Grossman WJ, Navickis RJ et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol: 2010; 137 21 30
29. Paul-Ehrlich-Institut (PEI) Stellungnahme vom 1.4.2011: Octagam 5% und 10%: Ruhen der Zulassung bis 29.07.2011 verlängert. http://www.pei.de Zugriff am 2.2.2012.
30. Plasma Protein Therapeutics Association (PPTA) Certification Program: Quality Standards of Excellence, Assurance, and Leadership (QSEAL). Program Description Version 1.6: 2010; http://www.pptaglobal.org Zugriff am 2.2.012.
31. Plasma Protein Therapeutics Association (PPTA) International Quality Plasma Program (IQPP) Certification, Program Description Version 2.1: 2012; http://www.pptaglobal.org Zugriff am 2.2.012.
32. Poelsler G, Berting A, Kindermann J et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang: 2008; 94 184 192 (Pubitemid 351379655)
33. Raanani P, Gafter-Gvili A, Paul M et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma: 2009; 50 764 772
34. Ravens-Sieberer U, Erhart M, Wille N et al. Generic health-related quality-of-life assessment in children and adolescents: methodological considerations. Pharmacoeconomics: 2006; 24 1199 1220 (Pubitemid 44901676)
35. Schmidt R, Baumann U. eds. Primäre und sekundäre Immundefekte. 2. Auflage Bremen Unimed-Verlag: 2009
36. Stangel M, Gold R, Baumann U et al. Treatment of neurological autoimmune diseases with immunoglobulins: insights from the prospective SIGNS registry. J Clin Immunol: 2012; (im Druck)
37. Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol: 1999; 56 661 663 (Pubitemid 29266463)
38. Stangel M. Einsatz intravenöser Immunglobuline in der Neurologie. Ein evidenzbasierter Konsens: Update 2010. Nervenarzt: 2010; 82 415 430
39. Verbsky J, Thakar M, Routes J. The Wisconsin approach to newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol: 2012; doi: 10.1016/j.jaci.2011.12.004
40. Vorstand der Bundesärztekammer auf Empfehlung des Wissenschaftlichen Beirats Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten. http://www.bundesaerztekammer.de Zugriff am 2.2.2012.